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NMP-7 inhibits chronic inflammatory and
neuropathic pain via block of Cav3.2 T-type
calcium channels and activation of CB2 receptors
N Daniel Berger1, Vinicius M Gadotti1, Ravil R Petrov2, Kevin Chapman1, Philippe Diaz2 and Gerald W Zamponi1*
Abstract
Background: T-type calcium channels and cannabinoid receptors are known to play important roles in chronic
pain, making them attractive therapeutic targets. We recently reported on the design, synthesis and analgesic
properties of a novel T-type channel inhibitor (NMP-7), which also shows mixed agonist activity on CB1 and CB2
receptors in vitro. Here, we analyzed the analgesic effect of systemically delivered NMP-7 (intraperitoneal (i.p.) or
intragstric (i.g.) routes) on mechanical hypersensitivity in inflammatory pain induced by Complete Freund’s Adjuvant
(CFA) and neuropathic pain induced by sciatic nerve injury.
Results: NMP-7 delivered by either i.p. or i.g. routes produced dose-dependent inhibition of mechanical hyperalgesia
in mouse models of inflammatory and neuropathic pain, without altering spontaneous locomotor activity in the
open-field test at the highest active dose. Neither i.p. nor i.g. treatment reduced peripheral inflammation per se, as
evaluated by examining paw edema and myeloperoxidase activity. The antinociception produced by NMP-7 in the
CFA test was completely abolished in CaV3.2-null mice, confirming CaV3.2 as a key target. The analgesic action of
intraperitoneally delivered NMP-7 was not affected by pretreatment of mice with the CB1 antagonist AM281, but
was significantly attenuated by pretreatment with the CB2 antagonist AM630, suggesting that CB2 receptors, but
not CB1 receptors are involved in the action of NMP-7 in vivo.
Conclusions: Overall, our work shows that NMP-7 mediates a significant analgesic effect in a model of persistent
inflammatory and chronic neuropathic pain by way of T-type channel modulation and CB2 receptor activation.
Thus, this study provides a novel therapeutic avenue for managing chronic pain conditions via mixed CB ligands/
T-type channel blockers.
Keywords: T-type calcium channels, Neuropathic pain, Inflammatory pain, Cannabinoid receptors, Analgesia
Background
Pathological chronic pain results from peripheral and
central alterations in the nociceptive pathway. This per-
sistent pain is difficult to treat and has a negative impact
on a patient’s quality of life, as well as economic impacts
associated with loss of productivity and cost of treatment.
Chronic inflammatory and chronic neuropathic pain re-
sults from tissue injury and nerve injury, respectively, and
both involve a peripheral and central sensitization event
that culminate in pain from normally innocuous stim-
uli, allodynia, or exacerbated pain from otherwise
mildly aversive stimuli, hyperalgesia [1]. The develop-
ment of novel analgesics is paramount to the effective
treatment of chronic pain, and the development of novel
molecular entities targeting multiple mechanisms of pain
neurobiology may be an attractive method to effectively
mediate pain with lower compound doses, and reduced
side effects [2].
Nociceptive transmission relies in part on low-voltage-
activated T-type calcium channels that open in response to
small membrane depolarizations [3]. T-type calcium chan-
nels are expressed along the primary afferent pain pathway
[4-6] and these channels—in particular T-type channel sub-
type CaV3.2—have shown potential as targets for analgesics
[6]. Selective antisense oligonucleotide-mediated CaV3.2
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knockdown [7,8] or inhibition of the T-type calcium chan-
nel by T-type channel modulators produce significant
antinociceptive effects in vivo [9-13]. Painful diabetic neu-
ropathies can be reversed by inhibiting T-type channels
[14] as well as by CaV3.2 antisense-mediated knockdown
[15]. CaV3.2 knockout mouse strains also show attenuated
pain responses in the formalin-induced pain model
[16]. Importantly, our laboratory has recently shown
that interfering with CaV3.2 channel trafficking medi-
ates analgesia in mouse models of inflammatory and
neuropathic pain [17].
In addition to T-type calcium channels, the cannabinoid
system has been recognized as a potential pharmaco-
logical target for chronic pain. The antinociceptive effects
of the cannabinoid system make it an attractive target for
relief of chronic pain, and randomized-controlled trials
have indeed shown that cannabis use results in significant
analgesia [18]. Interestingly, the endogenous cannabinoid
anandamide also modulates T-type channels directly to
produce thermal analgesia in a CaV3.2-dependent manner
[19,20]. Additionally, both Δ9-THC and cannabidiol [21]
or the endogenous cannabinoid anandamide and its de-
rivatives [20-22] inhibit T-type channel activity. The use
of such mixed CB/T-type calcium channel interacting
compounds may provide a strategy for the development
of better analgesics [23]. Indeed, combining different
mechanisms of action in a single drug could possess
several advantages that may include increased potency
and effect duration, with a reduction of side effects and
overall lower dose of the compound. In this context,
we have previously reported that a series of mixed T-
type channel inhibitors/cannabinoid receptor agonists,
including NMP-7 (Figure 1), dose-dependently reduce
formalin-induced nociception in mice [24]. NMP-7 was
determined in vivo to have potent T-type channel
blocking activity in electrophysiological measurements,
and a 10-fold higher preference for CB2 receptors over
CB1 receptors [24]. Here, we report on the antinocicep-
tive action of NMP-7 in a model of persistent inflamma-
tory pain and chronic neuropathic pain in mice, and
identify in vivo the underlying mechanism of action of this
compound.
Results
Analgesic effect of NMP-7 in persistent inflammatory pain
and chronic neuropathic pain
To determine whether NMP-7 mediates an antinociceptive
effect in mouse models of persistent inflammatory pain,
we analyzed mechanical hypersensitivity in CFA-injected
animals after systemic treatment with NMP-7. As shown
in Figure 2A, B, mice injected with CFA developed
mechanical hyperalgesia as indicated by a decrease in
paw withdrawal thresholds when compared to the pre-
CFA baseline levels of the vehicle control group (Two-way
ANOVA, p < 0.0001). Three days after CFA injection,
intraperitoneal treatment of mice with NMP-7 at 0.1
and 0.3 mg/kg significantly reversed mechanical hyper-
algesia induced by CFA from 30 minutes up to 1 hour
(p < 0.001 for 0.3 mg/kg) relative to vehicle-treated
controls (Figure 2A). Similarly, intragastric NMP-7 treat-
ment at 3 and 10 mg/kg significantly reversed mechanical
hyperalgesia from 30 minutes up to two hours after treat-
ment (p < 0.01 and p < 0.05 respectively for 10 mg/kg)
(Figure 2B). In contrast, treatment of mice with vehicle
control (PBS +5% DMSO) had no effect on the mechan-
ical hyperalgesia induced by CFA injection.
As seen in Figure 2C, partial sciatic nerve injury also
produced significant mechanical hypersensitivity in mice
when compared to sham-operated mice (p < 0.001). In-
traperitoneal administration of NMP-7 (0.3 mg/kg) sig-
nificantly decreased mechanical hyperalgesia from 30
minutes to two hours post-treatment, with a maximum
effect observed at one hour post-treatment (Two-way
ANOVA) (Figure 2C). Neither intraperitoneal (Figure 3A)
nor intragastric (Figure 3B) treatment of mice with
NMP-7 significantly altered the number of crossings in
the open field test with the active doses. Taken together,
these data show NMP-7 mediates a significant antino-
ciceptive effect against CFA-induced persistent inflam-
matory pain and neuropathic pain with no nonspecific
sedative or ataxic effects.
NMP-7 does not affect inflammation per se
To rule out the possibility that NMP-7 may directly
affect CFA-induced persistent inflammation we analyzed
the effects of NMP-7 on paw volume and MPO activity.
CFA injection 3 days prior to measurement produced
Figure 1 Chemical structure of NMP-7.
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significant paw edema (Two-way ANOVA, p < 0.0001) and
neutrophil infiltration (One-way ANOVA, p < 0.0001) when
compared to baseline measurements and PBS controls.
Treatment of mice with NMP-7 at the active doses 0.3 mg/
kg, i.p. (Figure 4A, C) or 10 mg/kg, i.g. (Figure 4B, D)
yielded no significant decrease in peripheral myeloperoxi-
dase levels (indicative of tissue neutrophil infiltration)
60 minutes post-treatment (Figure 4A, B), as well as no sig-
nificant decrease in paw volume as assessed by plethysm-
ometer (Figure 4C, D) relative to vehicle-treated control
animals. These results show that NMP-7 does not mediate
a direct peripheral anti-inflammatory effect.
The mechanism of NMP-7 action involves CaV3.2 T-type
calcium channels
To investigate whether the CaV3.2 T-type calcium channel
subtype is involved in NMP-7-mediated antinociception,
the analgesic effect of NMP-7 delivered systemically (i.p.)
was investigated in a CaV3.2 knockout mouse strain. In re-
sponse to CFA, these mice showed similar mechanical
withdrawal thresholds relative to wild-type mice (Figure 5),
as previously reported [17]. This is presumably due to
compensation from other ion channels (for example so-
dium channels, although this has not been experimentally
validated). Treatment with NMP-7 at 0.3 mg/kg, i.p. three
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Figure 2 Effect of intraperitoneal (A, C) or intragastric (B) treatment with NMP-7 on inflammatory pain and neuropathic pain. Each
point represents the mean ± SEM responses of 6–8 mice in Panels A, B and 6–12 mice in Panel C. Asterisks indicate significance relative to
vehicle-treated (PBS +5% DMSO) control group. *p < 0.05, **p < 0.01 and ***p < 0.001 when compared to vehicle-treated controls, ###p < 0.001
when comparing vehicle-treated control to sham group (Two-way ANOVA followed by a Tukey’s test).
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days post-CFA injection produced a significant inhibition
of mechanical hyperalgesia in wild type mice as expected
(Three-way ANOVA, p < 0.0001), however CaV3.2-null
mice showed complete insensitivity to NMP-7 treatment
(Figure 5A, B). These data validate CaV3.2 as a primary
target in the mechanism of NMP-7 action in vivo.
The mechanism of NMP-7 action involves CB2, but not
CB1 receptors
To determine the extent of CB receptor involvement in
NMP-7’s mechanism of action in vivo, the selective CB1
antagonist AM281 and the CB2 antagonist AM630 were
delivered to mice prior to NMP-7 treatment. Systemic
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Figure 4 Effect of intraperitoneal (A, C) or intragastric (B, D) treatment with NMP-7 on tissue myeloperoxidase (MPO) activity (Panel A
and B) and paw volume (Panel C and D). Bars represent mean ± SEM MPO units per mg of tissue (Panel A, B) and mean ± SEM of paw
volumes (Panel C, D) of 7–10 mice when NMP-7 was delivered i.p. and 4–5 mice when delivered i.g. ###p < 0.001 when compared to the
non-inflamed group (20 μl of PBS injected intraplantarily), ns = non significant relative to the inflamed vehicle-treated controls (PBS +5% DMSO).
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Figure 3 Effect of intraperitoneal (A) and intragastric (B) NMP-7 treatment in the open field test. Bars represent means ± SEM of total number
of crossings of 10–14 animals. Control values (black bars) represent vehicle-treated group (PBS +5% DMSO) (Student’s t-test, ns = non-significant).
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pretreatment of mice with AM630 (3 mg/kg, i.p.) sig-
nificantly attenuated the analgesic effects of NMP-7
(0.3 mg/kg, i.p.) at both 30 and 60 minutes post-treatment
(Two-way ANOVA, p < 0.01) (Figure 6A). AM630 also re-
versed the analgesic effect of URB597 (10 mg/kg, i.p., an
inhibitor of fatty acid amide hydrolase, the primary degra-
datory enzyme for the endocannabinoid anandamide),
which was used as positive control (Two-way ANOVA,
p < 0.01) (Figure 6A).
Systemic treatment of mice with the CB1 antagonist
AM281 (0.5 mg/kg i.p.) did not reverse the antinoci-
ceptive action of NMP-7 (0.3 mg/kg, i.p.) at both 30
and 60 minutes post-treatment (Figure 6B). Yet,
AM281 reversed the antinociceptive action of JZL184
(16 mg/kg, i.p., an irreversible inhibitor of monoacygly-
cerol lipase, the primary degradatory enzyme for endocan-
nabinoid 2-arachidonoylglycerol) (Two-way ANOVA,
p < 0.05) (Figure 6B), thus confirming that AM281 was
indeed active in vivo. These data suggest that CB2, but
not CB1 receptors are involved in the analgesic effect
of NMP-7.
Discussion
In this study, we have shown that the mixed CB agonist/
T-type calcium channel inhibitor NMP-7 is efficacious
in mediating analgesia in persistent inflammatory and
chronic neuropathic pain through a mechanism that is
dependent on CaV3.2 calcium channels and CB2 receptors,
but not CB1 receptors.
NMP-7 was previously characterized in an acute pain
model in mice (i.e., injection of formalin into the hind
paw) and was shown to attenuate both phases in a dose-
dependent fashion when delivered intrathecally [24]. The
effect in the second acute inflammatory phase of the for-
malin test suggested possible efficacy against persistent in-
flammatory pain. Indeed, as shown here, NMP-7 reversed
the mechanical hyperalgesia in the CFA model of persist-
ent inflammatory pain in a dose-dependent fashion for up
to one hour when administered intraperitoneally, and two
hours administered intragastrically. Furthermore, this
compound reversed mechanical hyperalgesia following
a peripheral nerve injury for up to two hours post-
treatment. When administered systemically, NMP-7 re-
sulted in significantly increased mechanical withdrawal
thresholds without mediating non-specific sedative or
ataxic effects at the active doses, as assessed by the open
field test.
Systemic, peripheral and intrathecal administration of
T-type calcium channel blockers such as mibefradil and
ethosuximide have been previously shown to reverse
mechanical and thermal hypersensitivity in response to
nerve injury [11]. Inhibition of T-type channels or in vivo
antisense-mediated knockdown produces antinociception
in these and other models of chronic pain [7-16]. Con-
versely, increased T-type channel activity in the primary
pain pathway occurs in models of chronic pain such as
spinal nerve injury [25], peripheral nerve injury [26], co-
lonic hypersensitivity [8] and diabetic neuropathy [27].
Altogether, these data indicate that T-type calcium chan-
nels mediate a pronociceptive role, and hence blockers
that target these channels have the propensity to mediate
analgesia. Along these lines, systemic and local adminis-
tration of CB2 receptor agonists have been reported to
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Figure 5 Time-dependent effect (A) and bar representation (B)
of NMP-7 delivered intraperitoneally to CaV3.2-null mice on
inflammatory pain. Each point (Panel A) represents the time
dependent mean ± SEM of mechanical withdrawal thresholds of
7–14 wild type or CaV3.2 null mice. Bars (Panel B) represent mean ± SEM
responses of mechanical withdrawal threshold measurements taken
30 minutes after i.p. treatment of wild type and CaV3.2 null mice with
vehicle (PBS +5% DMSO, black bars) or NMP-7 (white bars) (n = 7-14).
Asterisks indicate significance relative to vehicle control group,
***p < 0.001, ns = non significant (Three-way ANOVA for panel A and
Two-way ANOVA for panel B, followed by a Tukey’s test).
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produce analgesia in mice with peripheral nerve injuries,
altogether indicating that both T-type calcium channels
and CB2 receptors are important targets for treating
neuropathic pain [28]. Here we show that a single com-
pound, NMP-7, can target both of these pathways to trig-
ger analgesic effects in not only neuropathic pain, but also
hypersensitivity in response to CFA injection. Our data
show that NMP-7 mediates its antinociceptive action
largely through modulation of T-type calcium channels,
and in part by CB2 receptor activation. Indeed, CaV3.2-
null mice were completely insensitive to the NMP-7 treat-
ment and blocking CB2 receptors with AM630 also medi-
ated a significant (albeit incomplete) reduction in the
analgesic effects of this compound. This suggests that
although NMP-7-mediated activation of CB2 receptors
mediates analgesia, this may require the presence of
functional CaV3.2 channels. One possible explanation
could be that CB2 receptors mediate their analgesic ac-
tions by inhibiting CaV3.2 channels in afferent fibers. A
number of second messenger pathways have indeed
been shown to inhibit CaV3.2 channel activity [3]. Hence,
future studies should examine the possible coupling be-
tween CB2 receptors and T-type calcium channels in both
expression systems and in dorsal root ganglion neurons.
NMP-7 also mediated an antihyperalgesic effect for differ-
ent lengths of time when administered intraperitoneally
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Figure 6 Effect of pre-treatment of mice with selective CB2 (A) and CB1 (B) antagonists on the analgesic action of NMP-7. Each bar
represents mean ± SEM responses of 5–9 mice. Asterisks denote significance relative to vehicle-treated controls (PBS +5% DMSO), *p < 0.05,
**p < 0.01 , ***p < 0.001. #p < 0.05, ###p < 0.001 and ns = non significant when compared to antagonist-treated groups (Two-way ANOVA, followed
by a Tukey’s test).
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versus when administered intragastrically. This observed
difference in the duration of NMP-7 effects is likely due to
differential bioavailability of NMP-7; the pharmacokinetics
of NMP-7 may differ between the two routes of
administration.
CB1 receptors are expressed throughout the brain and
the spinal cord, where they modulate neurotransmitter
release such as inhibition of glutamate release by spinal
cord interneurons [29,30]. There is also evidence for
CB1 expression on nociceptors in the periphery [31].
However, CB1 receptors almost exclusively mediate
cannabis-related psychotropic effects, catalepsy and
motor ataxia [29]. Hence, activation of CB2 receptors
for pain relief is preferable to CB1 to avoid centrally-
mediated psychotropic effects, and suppress the peripheral
and central sensitization events that facilitate chronic pain
development. NMP-7 fits this pharmacological profile as
it binds to CB2 receptors with higher affinity than CB1
[24], and because of the inability of the CB1 receptor an-
tagonist AM281 to prevent NMP-7 action in vivo.
Conclusions
Taken together, NMP-7 mediates a pronounced analgesic
effect that is dependent on T-type CaV3.2 channels and
CB2 receptors, and appears to cause no nonspecific motor
effects at the therapeutic doses. Hence, T-type calcium
channel blockers with CB2 agonist activity such as NMP-7
may be a viable avenue for the development of new
chronic pain drugs.
Methods
Drugs and reagents
NMP-7 was synthesized at the Core Laboratory for
Neuromolecular Production at the University of Montana.
NMP-7 was dissolved in DMSO (to a maximum of 5%) and
PBS. Selective CB1 antagonist AM281, irreversible inhibitor
of monoacylglycerol lipase JZL184 [32,33], selective CB2 an-
tagonist AM630, and the irreversible inhibitor of fatty acid
amide hydrolase URB597 [34] were provided by Cayman
Chemical, and dissolved in phosphate buffered saline (PBS)
and dimethyl sulfoxide (DMSO) to 5%. Complete Freund’s
Adjuvant (CFA), o-Dianisidine and DMSO were supplied
by Sigma Aldrich. The myeloperoxidase (MPO) assay
standard was supplied by Calbiochem (EMD Millipore).
Animals and drug treatment
Experiments were conducted in accordance with a proto-
col approved by the University of Calgary’s Institutional
Animal Care and Use Committee, and all efforts were
made to minimize animal suffering according to the
policies and recommendations of the International As-
sociation for the Study of Pain. Adult male C57BL/6 J
(wild-type) or CACNA1H knockout (Cav3.2 null) mice
(20-25 g, 6–8 weeks) were used and purchased from
the Jackson Laboratory. Animals were housed at a max-
imum of five per cage (30 × 20 × 15 cm) with ad libitum
access to food and water. Animals were kept in controlled
temperature of 23 ± 1°C on a 12 h light/dark cycles (lights
on at 7:00 a.m.). When drugs were delivered by intraperi-
toneal (i.p.) and intragastric (i.g.) routes, a constant vol-
ume of 10 ml/kg body weight was injected. Appropriate
vehicle-treated groups were also assessed simultaneously.
All compounds, including NMP-7, were dissolved in
DMSO to a maximum 5% concentration, and PBS.
Control animals received PBS +5% DMSO, and sham
animals received no drug or vehicle. Choices of drug
doses were based on previous literature [35] and from
pilot experiments.
CFA-induced persistent inflammatory pain
To induce inflammatory chronic pain and paw swelling,
mice received a 20-μl injection of CFA subcutaneously in
the plantar surface of the right hindpaw (intraplantarily,
i.pl.). Control groups received 20 μl of PBS in the right
hindpaw. This CFA treatment produces significant paw
inflammation with accompanying hyperalgesia. Ani-
mals received NMP-7 either intraperitoneally (0.03 to
0.3 mg/kg) or intragastrically (1 to 10 mg/kg) 3 days
post-CFA injection.
Neuropathic pain induced by sciatic nerve injury
To induce chronic neuropathic pain, mouse sciatic nerves
were ligated according to Malmberg and Basbaum [36].
Briefly, mice were anesthetized under 4% isoflurane, and
held at 2.5% for the remainder of the surgery. The sciatic
nerve was exposed, and the distal one-third to one-half
section of the dorsal side of the nerve was transected and
tightly tied with silk sutures. Sciatic nerves were exposed
in sham-operated mice, but not tied. NMP-7 was adminis-
tered intraperitoneally (0.3 mg/kg) two weeks post-surgery
prior to testing mechanical withdrawal thresholds. Investi-
gators were blind to treatment conditions when measure-
ments were performed.
Measurement of mechanical hyperalgesia
For both the inflammatory and neuropathic pain models,
mechanical hyperalgesia was measured using the Dynamic
Plantar Aesthesiometer (Ugo Basile, Varese, Italy). Animals
were placed individually in a small, enclosed testing arena
(20 cm × 18.5 cm× 13 cm, length ×width × height) on top
of a wire mesh grid. Mice were allowed to acclimate for a
period of at least 90 minutes. The aesthesiometer device
was positioned beneath the animal such that the filament
was directly under the plantar surface of the ipsilateral hind
paw. Each paw was tested three to four times per session,
and measurements taken before the injuries were con-
sidered baseline measurements (B). Mice that had not
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developed persistent inflammatory or chronic neuropathic
pain were excluded prior to treatment.
Peripheral inflammation assays
In a different set of experiments from those described in
the preceding section, peripheral inflammation was in-
duced by a 20-μl injection of CFA subcutaneously in the
plantar surface of the right hindpaw (i.pl.). Control groups
received 20 μl of PBS in the right hindpaw. Mice received
NMP-7 systemically (0.3 mg/kg, i.p. or 10 mg/kg, i.g.)
3 days post-CFA treatment, and paw volume was deter-
mined 60 minutes post-treatment by plethysmometer.
For the MPO assay, CFA- or PBS-treated back right
hindpaws were collected 1 hour after NMP-7 administra-
tion at 0.3 mg/kg i.p. or 10 mg/kg i.g. Paws were homoge-
nized with EDTA/NaCl buffer (pH 7.4), centrifuged at
4400 g (15 mins, 4°C), and the pellet was resuspended in
ammonium bromide buffer (pH 5.4). The pellets were fro-
zen and thawed three times in liquid nitrogen, and after
the final thaw, re-centrifuged at 4400 g (15 mins, 4°C).
25 μl of the supernatant was assessed for MPO activity by
absorbance at 650 nm, with o-Dianisidine and 0.3 mM
H2O2 against an MPO standard.
Open field test
Mouse ambulatory behavior was assessed in an open-field
test as described previously [23]. The apparatus consisted
of a wooden box measuring 40 × 60 × 50 cm with a
frontal glass wall. The floor of the arena was divided into
12 equal squares and placed in a sound free room. Ani-
mals were placed in the rear left square and left to explore
freely for 6 minutes, during which time the number of
gridlines crossed with all paws (crossing) was counted.
The apparatus was cleaned with a 70% alcohol solution
and dried after each individual mouse session.
Analysis of mechanism of action
To address the role played by T-type channels in the
mechanisms by which NMP-7 produces antinociception,
we tested NMP-7 delivered systemically at the active
dose of 0.3 mg/kg in CaV3.2 null mice in the CFA test.
To investigate the involvement of CB1 receptor activa-
tion, the CB1 antagonist AM281 was administered alone
and with NMP-7. JZL184 was used as a positive control,
and was administered 15 minutes post-AM281 treatment
in the same way as NMP-7. To investigate the extent of
CB2 receptor involvement, the CB2 antagonist AM630
was delivered 15 minutes prior to NMP-7 treatment or
URB597 treatment, which was used as a positive control.
Data analysis
Each column or individual point (for line graphics) rep-
resents the mean ± SEM and is representative of at least
3 independent experimental runs. Data were evaluated
by One-way, Two-way or Three-way analysis of variance
(ANOVA) followed by the Tukey’s test, or alternatively a
two-sample Student’s t-test. A value of p < 0.05 was con-
sidered to be significant.
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